Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Latest Action
Read twice and referred to the Committee on Finance.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Ensuring Patient Access to Critical Breakthrough Products Act of 2024 is a Senate bill introduced in the 118th Congress aimed at improving patient access to important medical products classified as critical breakthroughs. The bill was read twice and referred to the Senate Committee on Finance but did not advance further and ultimately failed or expired. No official summary or full text is available, limiting detailed analysis of its provisions. The bill falls under the health policy area and appears intended to address regulatory or financial barriers to accessing breakthrough medical products.
This Senate bill sought to enhance patient access to critical breakthrough medical products but did not progress beyond committee referral and expired without enactment.
- Introduced in the Senate during the 118th Congress as S.5349.
- Focused on health policy, specifically patient access to breakthrough medical products.
- Referred to the Senate Committee on Finance after being read twice.
- No official summary or full text publicly available for detailed review.
- Status is recorded as failed or expired, indicating no legislative advancement.
['Patients requiring access to critical breakthrough medical products', 'Healthcare providers involved in delivering such treatments', 'Manufacturers and developers of breakthrough medical products', 'Health insurance entities potentially impacted by coverage policies']
['Lack of publicly available full text limits understanding of implementation mechanisms and funding sources', 'Unclear enforcement provisions or regulatory changes due to missing bill text', 'Potential cost implications for federal health programs or insurers are unknown', 'Oversight and authority details are not specified, complicating assessment of accountability']
The bill was introduced in the Senate and referred to the Committee on Finance, a key committee for health-related legislation involving financing and reimbursement. Its failure to advance suggests it did not gain sufficient legislative support or priority during the 118th Congress. The absence of a public summary or full text limits insight into the specific legislative intent or stakeholder positions.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could influence insurance coverage policies for breakthrough medical products, potentially affecting healthcare costs and access.', 'Changes to regulatory or reimbursement frameworks might impact pharmaceutical innovation incentives.', 'Healthcare providers might need to adjust treatment protocols based on access changes.']
The absence of both the full bill text and an official summary significantly limits transparency and public understanding of the bill's provisions and potential impacts. This lack of information impedes thorough oversight and informed public discourse. Additionally, the bill's failure to progress beyond committee referral highlights the importance of tracking legislative movement to assess policy relevance and priority.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.